Biomarkers for severe eosinophilic asthma.

Biomarkers for severe eosinophilic asthma.

The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or...

Bibliografiset tiedot
Päätekijät:	Yancey, S, Keene, O, Albers, F, Ortega, H, Bates, S, Bleecker, E, Pavord, I
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Elsevier 2017

Samankaltaisia teoksia

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Tekijä: Yancey, S, et al.
Julkaistu: (2016)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Tekijä: Ortega, H, et al.
Julkaistu: (2016)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Tekijä: Gunsoy, N, et al.
Julkaistu: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
Tekijä: Shrimanker, R, et al.
Julkaistu: (2018)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Tekijä: Pavord, I, et al.
Julkaistu: (2012)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Tekijä: Ortega, H, et al.
Julkaistu: (2014)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Tekijä: Bel, E, et al.
Julkaistu: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Tekijä: Steven W. Yancey, et al.
Julkaistu: (2019-09-01)

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
Tekijä: Shrimanker, R, et al.
Julkaistu: (2019)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Tekijä: Bel, E, et al.
Julkaistu: (2014)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Tekijä: Pavord, I
Julkaistu: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Tekijä: Howell, I, et al.
Julkaistu: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Tekijä: Prazma CM, et al.
Julkaistu: (2021-06-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Tekijä: Imran Howell, et al.
Julkaistu: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Tekijä: Terufumi Shimoda, et al.
Julkaistu: (2017-07-01)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
Tekijä: Charlene M. Prazma, et al.
Julkaistu: (2019-05-01)

Eosinophils in asthma and airway hyperresponsiveness.
Tekijä: Brightling, C, et al.
Julkaistu: (2004)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
Tekijä: Rastogi, S, et al.
Julkaistu: (2017)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
Tekijä: Kulkarni, N, et al.
Julkaistu: (2010)

Non-eosinophilic asthma and the innate immune response.
Tekijä: Pavord, I
Julkaistu: (2007)

Severe eosinophilic asthma: a roadmap to consensus.
Tekijä: Buhl, R, et al.
Julkaistu: (2017)

Mepolizumab in refractory eosinophilic asthma.
Tekijä: Pavord, I, et al.
Julkaistu: (2010)

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma
Tekijä: Luo, J, et al.
Julkaistu: (2024)

A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels
Tekijä: Haughney, J, et al.
Julkaistu: (2017)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Tekijä: Mi-Kyeong Kim, et al.
Julkaistu: (2021-03-01)

Eosinophilic bioactivities in severe asthma
Tekijä: Tara F. Carr, et al.
Julkaistu: (2016-01-01)

Non-eosinophilic corticosteroid unresponsive asthma.
Tekijä: Pavord, I, et al.
Julkaistu: (1999)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Tekijä: Shrimanker, R, et al.
Julkaistu: (2017)

Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies
Tekijä: Pavord, I, et al.
Julkaistu: (2019)

Eosinophils in asthma and other allergic diseases.
Tekijä: Wardlaw, A, et al.
Julkaistu: (2000)

The significance of eosinophilic airway inflammation in asthma
Tekijä: Pavord, I, et al.
Julkaistu: (2002)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
Tekijä: Brightling, C, et al.
Julkaistu: (2003)

Asthma heterogeneity and severity
Tekijä: Tara F. Carr, et al.
Julkaistu: (2016-01-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Tekijä: Pavord, I, et al.
Julkaistu: (2017)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
Tekijä: Frank C. Albers, et al.
Julkaistu: (2019-07-01)

Eosinophils in COPD: just another biomarker?
Tekijä: Bafadhel, M, et al.
Julkaistu: (2017)

Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants.
Tekijä: Anees, W, et al.
Julkaistu: (2002)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Tekijä: Moran, AM, et al.
Julkaistu: (2020)

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
Tekijä: Lavoie, G, et al.
Julkaistu: (2024)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Tekijä: Shrimanker, R, et al.
Julkaistu: (2017)